Zoledronic acid-d3
Based on 1 Customer Validation
Zoledronic acid-d3 (Zoledronate-d3) is the deuterium labeled Zoledronic acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1134798-26-7
- 화학식: C5H7D3N2O7P2
- 분자량:275.11
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1134798-26-7
-
Unlabeled Cas 118072-93-8
-
분자량 275.11
-
화학식 C5H7D3N2O7P2
-
SMILES
OC(P(O)(O)=O)(P(O)(O)=O)CN1C([2H])=C([2H])N=C1[2H]
-
Synonyms
Zoledronate-d3; CGP 42446-d3; CGP42446A-d3; ZOL 446-d3
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
용액&용해도
H2O : 4.17 mg/mL (15.16 mM; ultrasonic and warming and heat to 60°C)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
References
[1]. Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059. [Content Brief]
[2]. Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20(6): 1467. [Content Brief]
[3]. Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44(2):582-592. [Content Brief]
[4]. XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13(1): 613-622. [Content Brief]
[5]. Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15(18):5829-39. [Content Brief]
[6]. Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.6349 mL | 18.1745 mL | 36.3491 mL | 90.8727 mL |
| 5 mM | 0.7270 mL | 3.6349 mL | 7.2698 mL | 18.1745 mL | |
| 10 mM | 0.3635 mL | 1.8175 mL | 3.6349 mL | 9.0873 mL | |
| 15 mM | 0.2423 mL | 1.2116 mL | 2.4233 mL | 6.0582 mL |
Zoledronic acid-d3 Related Classifications
HY-13777S1 Related Classifications
Powered by Bioz